UNMC is now a registered participant for Eli Lilly and Company’s new Phenotypic Drug Discovery (PD2) program.
Eli Lilly — one of the world’s largest pharmaceutical companies — has launched the initiative to identify new molecules that display activity in relevant disease models and that can serve as a foundation for the development of research collaborations between the company and external researchers for the development of new therapies.
The program lets UNMC researchers submit potential therapeutic compounds for phenotypic drug screening. Researchers can submit compound structures by completing a New Invention Notification (NIN) through the UNeMed office. NIN forms are available online at www.unemed.com.
|
If selected by Eli Lilly, the compounds will be screened for activity in five phenotypic assay modules:
- Alzheimer’s disease;
- Cancer (cell cycle arrest);
- Cancer (Anti-Angiogensis);
- Diabetes; and
- Bone Formation.
Promising results may lead to a license agreement or collaboration between Eli Lilly and UNMC to further develop the drug molecules.
UNMC researchers interested in the program can contact licensing specialist Matt Boehm, Ph.D., at mboehm@unmc.edu or 559-2166 for more information.
“The PD2 program provides a unique opportunity for UNMC researchers to gain valuable information about their compounds,” Dr. Boehm said. “This initiative also gives us a potential route to develop collaborations with a major pharmaceutical company.”